UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,480	02/06/2004	Michel Dib	FRAV2003/0003 US NP	7069
5487 ROSS J. OEHL	7590 06/18/200 LER	7 `	EXAM	IINER
	NTIS U.S. LLC	KIM, JENNIFER M		
1041 ROUTE 202-206 MAIL CODE: D303A BRIDGEWATER, NJ 08807			ART UNIT	PAPER NUMBER
			1617	
	•		NOTIFICATION DATE	DELIVERY MODE
			06/18/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com andrea.ryan@sanofi-aventis.com

		Application No.	Applicant(s)			
		10/773,480	DIB ET AL.			
	Office Action Summary	Examiner	Art Unit			
	·	Jennifer Kim	1617			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. of period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
1)🖂	Responsive to communication(s) filed on 06 Fe	ebruary 2004.				
2a) <u></u> ☐	This action is FINAL . 2b) This action is non-final.					
3)[Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	ion of Claims					
5) 6) 7)	Claim(s) <u>1-20</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-20</u> are subject to restriction and/or expressions.	vn from consideration.				
Application Papers						
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).			
Priority (inder 35 U.S.C. & 119					
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachmen	t(s) ee of References Cited (PTO-892)	4) 🔲 Interview Summary	y (PTO-413)			
2) Notice 3) Information	te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) or No(s)/Mail Date	Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	oate			

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-7, drawn to a method of treating a patient for **sleep disorders** comprising administering to said patient a therapeutically effective amount of a 2-cyano-10-(2-methyl-3-(methylamino)propyl)phenothiazine (I) or a pharmaceutically acceptable salt thereof, classified in class 514, subclass 226.2.
- II. Claims 8, 9, 16 and 17, drawn to a method of treating a patient suffering from anxiety disorder, classified in class 514, subclass 226.2.
- III. Claims 8, 10, 16 and 17, drawn to a method of treating a patient suffering from **mood disorder**, classified in class 514, subclass 226.2.
- IV. Claims 8, 11, 16 and 17, drawn to a method of treating a patient suffering from mixed anxiety-depression disorder, classified in class 514, subclass 226.2.
- V. Claims 8, 12, 16 and 17, drawn to a method of treating a patient suffering from acute and chronic psychotic state, classified in class 514, subclass 226.2.

- VI. Claims 8, 13, 16 and 17, drawn to a method of treating a patient suffering from addiction to and withdrawal from a substance, classified in class 514, subclass 226.2.
- VII. Claims 8, 14, 16 and 17, drawn to a method of treating a patient suffering from an extrapyramidal event induced by an antipsychotic, classified in class 514, subclass 226.2.
- VIII. Claims 8, 15, 16 and 17, drawn to a method of treating a patient suffering from a symptomacti dimension during acute or chronic psychotic state as monotherapy, classified in class 514, subclass 226.2.
- IX. Claims 18-20, drawn to a **method for preparing a medicament**comprising a mixing a therapeutically effective amount of 2-cayno-10-(2-methyl-3-(methylamino)-propyl)phenothiazine or a pharmaceutically acceptable salt thereof with one or more compatible and pharmaceutically acceptable diluents or adjuvants, classified in class 514, subclass 226.2.

The inventions are distinct, each from the other because of the following reasons:

Inventions Group I-VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different effects because each of the medical disorders to be treated have unrelated biological pathways and different target cell, and have known different etiology.

Inventions Group I-VIII and Groups IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different operations because Groups I-VIII are drawn to the treatment of medical disorder involving human body while Group IX is related to manufacturing or process of preparing a medicament.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Kim Patent Examiner Art Unit 1617